Genexine’s COVID-19 drug to begin phase 1 trial in KoreaBy Lim Jeong-yeo
Published : Aug. 7, 2020 - 18:09
GX-17 is a protein drug recombining human IL-7 and hybrid Fc (hyFc) that the company had been developing as an anti-cancer treatment. It is a T-Cell growth factor that proliferates a patient‘s immune cells, by which it slows the progression of an illness and hastens recovery.
With the addition of GX-17, South Korea now has 13 treatment researches and two vaccine researches ongoing to tackle COVID-19.
By Lim Jeong-yeo (firstname.lastname@example.org)
Key doctors’ group to hold mass protest on March 3
Yoon bets big on nuclear energy
Gender Ministry on course for disbandment